Bogdan Panaitescu1,2, Roberto Romero1,3,4,5, Nardhy Gomez-Lopez1,2,6, Percy Pacora1,2, Offer Erez1,2, Felipe Vadillo-Ortega1, Lami Yeo1,2, Sonia S Hassan1,2,7, Chaur-Dong Hsu2. 1. Perinatology Research Branch, NICHD/NIH/DHHS, Detroit, MI, USA. 2. Department of Obstetrics & Gynecology, Wayne State University School of Medicine, Detroit, MI, USA. 3. Department of Obstetrics & Gynecology, University of Michigan, Ann Arbor, MI, USA. 4. Department of Epidemiology & Biostatistics, Michigan State University, East Lansing, MI, USA. 5. Center for Molecular Medicine & Genetics, Wayne State University, Detroit, MI, USA. 6. Department of Immunology, Microbiology & Biochemistry, Wayne State University School of Medicine, Detroit, MI, USA. 7. Department of Physiology, Wayne State University School of Medicine, Detroit, MI, USA.
Abstract
Objective: ELABELA is a newly discovered peptide hormone that appears to be implicated in the mechanisms leading to preeclampsia, independently of angiogenic factors. The aim of the current study was to investigate whether women with early- or late-onset preeclampsia have altered ELABELA plasma concentrations compared to gestational-age-matched normal pregnant women. Methods: This retrospective cross-sectional study focused on the maternal plasma samples collected from 232 women with a singleton pregnancy who were allocated into the following groups: (1) early-onset preeclampsia (<34 weeks of gestation, N = 56); (2) late-onset preeclampsia (≥34 weeks of gestation, N = 57); and (3) gestational-age-matched controls with a normal pregnancy [(<34 weeks of gestation, N = 59); (≥34 weeks of gestation, N = 60)]. ELABELA plasma concentrations were determined using a validated enzyme immunoassay. Results: (1) ELABELA plasma concentrations are higher in patients with late-onset preeclampsia compared with those from gestational-age-matched controls with a normal pregnancy [median: 7.99 ng/mL (IQR, 5.3-13.95 ng/mL) versus median: 4.17 ng/mL (IQR, 3-11.19 ng/mL), p =.001]; (2) ELABELA plasma concentrations in patients with early-onset preeclampsia do not differ from those of normal pregnant women [median: 6.09 ng/mL (IQR, 2.8-10.66 ng/mL) versus median: 4.02 ng/mL (IQR, 3.26-7.49), p = .32]; and (3) ELABELA plasma concentrations are higher in patients with late-onset preeclampsia compared to those with early-onset preeclampsia [median: 7.99 ng/mL (IQR, 5.3-13.95 ng/mL) versus median: 6.09 ng/mL (IQR, 2.8-10.66 ng/mL), p = .01]. Conclusion: ELABELA plasma concentrations are higher in patients with late-onset preeclampsia than in those with a normal pregnancy. However, women with early-onset preeclampsia have similar ELABELA plasma concentrations to those with a normal pregnancy. These findings provide insight into the ELABELA axis during the human syndrome of preeclampsia. In addition, these data support the concept that different pathophysiologic mechanisms are implicated in early- and late-onset preeclampsia.
Objective: ELABELA is a newly discovered peptide hormone that appears to be implicated in the mechanisms leading to preeclampsia, independently of angiogenic factors. The aim of the current study was to investigate whether women with early- or late-onset preeclampsia have altered ELABELA plasma concentrations compared to gestational-age-matched normal pregnant women. Methods: This retrospective cross-sectional study focused on the maternal plasma samples collected from 232 women with a singleton pregnancy who were allocated into the following groups: (1) early-onset preeclampsia (<34 weeks of gestation, N = 56); (2) late-onset preeclampsia (≥34 weeks of gestation, N = 57); and (3) gestational-age-matched controls with a normal pregnancy [(<34 weeks of gestation, N = 59); (≥34 weeks of gestation, N = 60)]. ELABELA plasma concentrations were determined using a validated enzyme immunoassay. Results: (1) ELABELA plasma concentrations are higher in patients with late-onset preeclampsia compared with those from gestational-age-matched controls with a normal pregnancy [median: 7.99 ng/mL (IQR, 5.3-13.95 ng/mL) versus median: 4.17 ng/mL (IQR, 3-11.19 ng/mL), p =.001]; (2) ELABELA plasma concentrations in patients with early-onset preeclampsia do not differ from those of normal pregnant women [median: 6.09 ng/mL (IQR, 2.8-10.66 ng/mL) versus median: 4.02 ng/mL (IQR, 3.26-7.49), p = .32]; and (3) ELABELA plasma concentrations are higher in patients with late-onset preeclampsia compared to those with early-onset preeclampsia [median: 7.99 ng/mL (IQR, 5.3-13.95 ng/mL) versus median: 6.09 ng/mL (IQR, 2.8-10.66 ng/mL), p = .01]. Conclusion:ELABELA plasma concentrations are higher in patients with late-onset preeclampsia than in those with a normal pregnancy. However, women with early-onset preeclampsia have similar ELABELA plasma concentrations to those with a normal pregnancy. These findings provide insight into the ELABELA axis during the humansyndrome of preeclampsia. In addition, these data support the concept that different pathophysiologic mechanisms are implicated in early- and late-onset preeclampsia.
Authors: P Pacora; T Chaiworapongsa; E Maymon; Y M Kim; R Gomez; B H Yoon; F Ghezzi; S M Berry; F Qureshi; S M Jacques; J C Kim; N Kadar; R Romero Journal: J Matern Fetal Neonatal Med Date: 2002-01
Authors: Angela Makris; Kristen R Yeung; Shirlene M Lim; Neroli Sunderland; Scott Heffernan; John F Thompson; Jim Iliopoulos; Murray C Killingsworth; Jim Yong; Bei Xu; Robert F Ogle; Ravi Thadhani; S Ananth Karumanchi; Annemarie Hennessy Journal: Hypertension Date: 2016-04-18 Impact factor: 10.190
Authors: Duuamene Nyimanu; Richard G Kay; Rhoda E Kuc; Alastair J H Brown; Fiona M Gribble; Janet J Maguire; Anthony P Davenport Journal: Peptides Date: 2021-08-26 Impact factor: 3.750